Replimune Group Stock Current Valuation
| REPL Stock | USD 13.24 0.25 1.85% |
Valuation analysis of Replimune Group helps investors to measure Replimune's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is expected to rise to about 527.2 M this year, although Enterprise Value Over EBITDA will most likely fall to (2.12). Fundamental drivers impacting Replimune's valuation include:
Undervalued
Today
Please note that Replimune's price fluctuation is not too volatile at this time. Calculation of the real value of Replimune Group is based on 3 months time horizon. Increasing Replimune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Replimune stock is determined by what a typical buyer is willing to pay for full or partial control of Replimune Group. Since Replimune is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Replimune Stock. However, Replimune's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.24 | Real 17.15 | Target 18.38 | Hype 13.49 | Naive 12.71 |
The intrinsic value of Replimune's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Replimune's stock price.
Estimating the potential upside or downside of Replimune Group helps investors to forecast how Replimune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Replimune more accurately as focusing exclusively on Replimune's fundamentals will not take into account other important factors: Replimune Group Company Current Valuation Analysis
Replimune's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Replimune Current Valuation | 587.67 M |
Most of Replimune's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Replimune Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Replimune Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Replimune is extremely important. It helps to project a fair market value of Replimune Stock properly, considering its historical fundamentals such as Current Valuation. Since Replimune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Replimune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Replimune's interrelated accounts and indicators.
Click cells to compare fundamentals
Replimune Current Valuation Historical Pattern
Today, most investors in Replimune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Replimune's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Replimune current valuation as a starting point in their analysis.
Replimune Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Replimune Group has a Current Valuation of 587.67 M. This is 95.91% lower than that of the Biotechnology sector and 87.35% lower than that of the Health Care industry. The current valuation for all United States stocks is 96.46% higher than that of the company.
Replimune Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Replimune's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics of similar companies.Replimune is currently under evaluation in current valuation category among its peers.
Replimune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Replimune from analyzing Replimune's financial statements. These drivers represent accounts that assess Replimune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Replimune's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 886.6M | 1.0B | 514.6M | 463.1M | 568.6M | |
| Enterprise Value | 1.3B | 813.5M | 942.2M | 516.0M | 464.4M | 527.2M |
Replimune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Replimune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Replimune's managers, analysts, and investors.Environmental | Governance | Social |
Replimune Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 587.67 M | ||||
| Shares Outstanding | 77.01 M | ||||
| Shares Owned By Insiders | 4.17 % | ||||
| Shares Owned By Institutions | 95.83 % | ||||
| Number Of Shares Shorted | 8.47 M | ||||
| Price To Book | 2.17 X | ||||
| EBITDA | (230.2 M) | ||||
| Net Income | (215.79 M) | ||||
| Cash And Equivalents | 395.08 M | ||||
| Cash Per Share | 8.01 X | ||||
| Total Debt | 75.87 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 19.79 X | ||||
| Book Value Per Share | 6.26 X | ||||
| Cash Flow From Operations | (185.47 M) | ||||
| Short Ratio | 9.80 X | ||||
| Earnings Per Share | (3.07) X | ||||
| Target Price | 20.88 | ||||
| Number Of Employees | 331 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 1.04 B | ||||
| Total Asset | 487.72 M | ||||
| Retained Earnings | (701.28 M) | ||||
| Working Capital | 393.23 M | ||||
| Net Asset | 487.72 M |
About Replimune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Replimune Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Replimune Piotroski F Score and Replimune Altman Z Score analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.